NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy

[1]  A. Carayon,et al.  Beta-adrenoceptor blockade potentiates exercise-induced release of atrial natriuretic peptide , 2004, European Journal of Clinical Pharmacology.

[2]  Pedro Lozano.  Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[3]  P. Macfarlane,et al.  Can natriuretic peptides be used to monitor the response to carvedilol in patients with ischaemic left ventricular systolic dysfunction , 2002 .

[4]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[5]  S. Yusuf,et al.  Natriuretic peptides predict left ventricular remodeling in response to metoprolol CR in patients with congestive heart failure: the RESOLVD phase II neurohumoral substudy , 2002 .

[6]  A. Maggioni,et al.  Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure , 2002, Clinical chemistry and laboratory medicine.

[7]  H. Kawai,et al.  Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. , 2001, American heart journal.

[8]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[9]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[10]  A. Spurkland,et al.  Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. , 2001, Acta physiologica Scandinavica.

[11]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[12]  D. Barnett,et al.  Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. , 2000, European heart journal.

[13]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[14]  D. Murdoch,et al.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.

[15]  E. Nylander,et al.  The circulating renin–angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non‐ischaemic dilated cardiomyopathy , 1999, Journal of internal medicine.

[16]  J G Turner,et al.  Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction , 1999, Heart.

[17]  J. Karl,et al.  Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. , 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[18]  H. Hense,et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. , 1998, Journal of the American College of Cardiology.

[19]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[20]  M. Komajda,et al.  Risk stratification in chronic heart failure. , 1998, European heart journal.

[21]  A. Richards,et al.  The Role of the Circulation in Processing pro-Brain Natriuretic Peptide (proBNP) to Amino-Terminal BNP and BNP-32 , 1997, Peptides.

[22]  R. Doughty,et al.  Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment , 1997, Clinical endocrinology.

[23]  N. Arakawa,et al.  Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. , 1996, Journal of the American College of Cardiology.

[24]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[25]  H. Krumholz,et al.  Epidemiologic and economic impact of advanced heart failure. , 1996, The Journal of cardiovascular nursing.

[26]  A. Richards,et al.  The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. , 1995, Biochemical and biophysical research communications.

[27]  M. Horiuchi,et al.  Atrial Natriuretic Peptide and Antihypertensive Action Due to β-Blockade in Essential Hypertensive Patients , 1995 .

[28]  M. Horiuchi,et al.  Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. , 1995, Angiology.

[29]  G. Lamas,et al.  Activation of neurohumoral systems in postinfarction left ventricular dysfunction. , 1993, Journal of the American College of Cardiology.

[30]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[31]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[32]  G. Francis.  Neuroendocrine activity in congestive heart failure. , 1990, The American journal of cardiology.

[33]  M. Packer,et al.  Neurohormonal interactions and adaptations in congestive heart failure. , 1988, Circulation.

[34]  K. Imataka,et al.  Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. , 1987, Hypertension.

[35]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[36]  K. Kangawa,et al.  Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP) , 1984 .

[37]  K. Kangawa,et al.  Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). , 1984, Biochemical and biophysical research communications.